Although follow-up after discharge was limited due to the patient’s decision to discontinue treatment, the available clinical and molecular data provide valuable insights into the phenotypic and genetic spectrum of NARS2-related COXPD24. Here, NARS2 is linked to Combined oxidative phosphorylation defect type 24.